Literature DB >> 15516859

The effects of beta blockers on morbidity and mortality in heart failure.

Syed M Jafri1.   

Abstract

Beta-adrenergic receptor blockers are effective in reducing morbidity and mortality in heart failure. These drugs slow the progression of heart failure by modifying the remodeling process, prevent or delay need for hospital admission for heart failure. They reduce both pump failure and sudden arrhythmic death. There are many patients that do not receive beta blocker therapy in the heart failure population. Patients are often treated with beta blockers not tested in clinical trials to demonstrate efficacy in this patient population. Results from the recently published trials are summarized to emphasize the proper selection and dosage of beta blocker therapy to optimize the care of this high risk population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516859     DOI: 10.1023/B:HREV.0000046366.31764.ca

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  14 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.

Authors:  W Kao; M Gheorghiade; V Hall; S Goldstein
Journal:  Am J Cardiol       Date:  1989-09-15       Impact factor: 2.778

3.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.

Authors:  K Chadda; S Goldstein; R Byington; J D Curb
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

4.  Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction.

Authors:  S Goldstein; H L Kennedy; C Hall; J L Anderson; M Gheorghiade; S Gottlieb; M Jessup; R P Karlsberg; G Friday; L Haskell
Journal:  Am Heart J       Date:  1999-12       Impact factor: 4.749

5.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.

Authors:  S L Woodley; E M Gilbert; J L Anderson; J B O'Connell; D Deitchman; F G Yanowitz; P C Mealey; K Volkman; D G Renlund; R Menlove
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

6.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

7.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

8.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Authors:  Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Peter Hanrath; Michel Komajda; Jacobus Lubsen; Beatrix Lutiger; Marco Metra; Willem J Remme; Christian Torp-Pedersen; Armin Scherhag; Allan Skene
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

9.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

10.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors:  A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

View more
  5 in total

1.  Effect of Haimiding on the functioning of red cell membrane of FC and H22 tumor-bearing mice.

Authors:  Yu-Bin Ji; Shi-Yong Gao; Wei-Ping Cheng
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

Review 2.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

3.  β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats.

Authors:  Yuan Du; Junbo Zhang; Yutao Xi; Geru Wu; Ke Han; Xin Huang; Aiqun Ma; Tingzhong Wang
Journal:  J Physiol Biochem       Date:  2016-03-19       Impact factor: 4.158

Review 4.  Sympathetic activation in congestive heart failure: an updated overview.

Authors:  Guido Grassi; Fosca Quarti-Trevano; Murray D Esler
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

Review 5.  Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.

Authors:  Saurav Chatterjee; Giuseppe Biondi-Zoccai; Antonio Abbate; Fabrizio D'Ascenzo; Davide Castagno; Benjamin Van Tassell; Debabrata Mukherjee; Edgar Lichstein
Journal:  BMJ       Date:  2013-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.